Skip to main content
Evidence Snapshot

Sphingosine 1-phosphate receptor 1

CHEMBL4333 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T14:20:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4333
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sphingosine 1-phosphate receptor 1 as ChEMBL target CHEMBL4333, mapped to UniProt P21453. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sphingosine 1-phosphate receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4333
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21453
Sphingosine 1-phosphate receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Sphingosine 1-phosphate receptor 1 matters

As of 2026-09-13

Sphingosine 1-phosphate receptor 1 is reviewed as Sphingosine 1-phosphate receptor 1 (UniProt P21453); Sphingosine 1-phosphate receptor 1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 9 approved drugs, 4566 compounds, and 384 assays, with lead potency reaching pChEMBL 11.0.

Disease context
multiple sclerosis

Sphingosine 1-phosphate receptor 1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include OZANIMOD HYDROCHLORIDE, PONESIMOD, SIPONIMOD.

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include OZANIMOD HYDROCHLORIDE, PONESIMOD, SIPONIMOD, SIPONIMOD FUMARIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 4566 compounds, and 384 assays for this target. The dominant activity type is EC50. CHEMBL2032300 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL2032300 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Sphingosine 1-phosphate receptor 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21453, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why multiple sclerosis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

4566
Total Compounds
384
Total Assays
9
Approved Drugs
IC50: 1814.0, KI: 146.0, EC50: 3607.0, KD: 9.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2032300
 11.0 EC50 —
No preferred name
CHEMBL3806205
 11.0 IC50 —
No preferred name
CHEMBL3403631
 11.0 IC50 —
No preferred name
CHEMBL366208
 10.9 EC50 —
No preferred name
CHEMBL2018176
 10.9 EC50 —

Approved Drugs

Structure Compound First Approval
ETRASIMOD
CHEMBL3358920
 2023
PONESIMOD
CHEMBL1096146
 2021
OZANIMOD
CHEMBL3707247
 2020
SIPONIMOD
CHEMBL2336071
 2019
FINGOLIMOD
CHEMBL314854
 2010
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T14:20:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4333